For the past several years, a clinical trial from Washington University (St. Louis) has been underway in people with genetic mutations that lead to early-onset Alzheimer's. The Dominantly Inherited Alzheimer's Network (Trials Unit), DIAN-TU, has been dosing 194 such patients with one of two anti-amyloid antibodies, either Lilly's (LLY) solanezumab or Roche/Genentech's (RHHBY) (RHHBF) gantenerumab (or placebo), and looking for signs of slowing cognitive decline. Here's a blog post back when that started.
Results were announced February 10, and sadly you already know what they are. No effect for either drug, the doses of which